An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies

Journal of Medical Genetics
Maria J BakerJoseph J Drabick

Abstract

Familial atypical multiple mole melanoma syndrome (FAMMM) is characterised by dysplastic naevi, malignant melanoma and pancreatic cancer. Given that large deletions involving CDKN2A (cyclin-dependent kinase inhibitor 2A) account for only 2% of cases, we describe a family that highlights the co-occurrence of both melanoma and neural system tumours to aid clinical recognition and propose a management strategy. A patient with multiple neurofibromas was referred with a provisional diagnosis of neurofibromatosis type 1 (NF1). Prior molecular testing, though, had failed to identify an NF1 mutation by sequencing and multiplex ligation-dependent probe amplification. His family history was significant for multiple in situ/malignant melanomas at young ages and several different cancers reminiscent of an underlying syndrome. A search of the Familial Cancer Database, FaCD Online, highlighted several families with cutaneous melanoma and nervous system tumours who were subsequently identified to have large deletions spanning CDKN2A Although sequencing of CDKN2A and TP53 failed to identify a mutation, a heterozygous CDKN2A deletion was identified by targeted array comparative genomic hybridisation (CGH). Whole-genome oligonucleotide array CGH...Continue Reading

References

Nov 13, 1992·Science·L A Cannon-AlbrightA E Bale
Oct 12, 1995·The New England Journal of Medicine·A M GoldsteinW H Clark
Sep 1, 1994·Nature Genetics·C J HussussianN C Dracopoli
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F KeffordM A Tucker
Jan 4, 2001·Human Molecular Genetics·J A Randerson-MoorD T Bishop
Oct 2, 2001·Genes, Chromosomes & Cancer·S AuroyUNKNOWN French Hereditary Melanoma Study Group
May 16, 2002·Journal of Medical Genetics·D G R EvansA Moran
Jun 20, 2002·Journal of the National Cancer Institute·D Timothy BishopUNKNOWN Melanoma Genetics Consortium
Jun 6, 2003·Oncogene·Nicholas K Hayward
Aug 20, 2003·Archives of Dermatology·Jana Foley ParkerSancy A Leachman
Oct 24, 2003·Familial Cancer·R H Sijmons, G T Burger
Oct 30, 2003·Cancer·Henry T LynchZoran Gatalica
Feb 12, 2004·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Rafał CzajkowskiGrazyna Uchańska
Jul 21, 2005·Genes, Chromosomes & Cancer·Sushila H MistryD Timothy Bishop
Oct 20, 2005·Journal of the National Cancer Institute·Colin B BeggUNKNOWN Genes Environment and Melanoma Study Group
Jun 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Saba SharifD Gareth R Evans
Oct 19, 2006·Cancer Research·Alisa M GoldsteinUNKNOWN Melanoma Genetics Consortium (GenoMEL)
Aug 2, 2008·The Surgical Clinics of North America·Johan Hansson
Jun 6, 2009·Cancer Letters·Isabella EckerleFrank Westermann
Jul 30, 2010·International Journal of Cancer. Journal International Du Cancer·Anne E CustGraham J Mann
Aug 30, 2011·Nature Genetics·Thomas WiesnerMichael R Speicher
Jan 26, 2013·Science·Susanne HornRajiv Kumar
Apr 25, 2013·American Journal of Medical Genetics. Part a·Rachel VannesteGail Graham
Apr 2, 2014·Nature Genetics·Jianxin ShiMaria Teresa Landi
Apr 2, 2014·Nature Genetics·Carla Daniela Robles-EspinozaDavid J Adams
Jun 3, 2014·BMC Medical Genetics·Simona FrigerioMonica Rodolfo
Apr 1, 2009·Retinal Cases & Brief Reports·Christopher N SinghRobert E Kalina

❮ Previous
Next ❯

Citations

Jun 15, 2017·Journal of Immunoassay & Immunochemistry·Carmen DumitruMonica Neagu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.